https://www.selleckchem.com/products/sw-100.html
Four medications are FDA approved for bipolar depression lurasidone (LUR), cariprazine (CAR), quetiapine IR XR (QUE), and olanzapine-fluoxetine combination (OFC). Indirect comparisons for efficacy using Number Needed to Treat (NNT) and for tolerability using Number Needed to Harm (NNH) can be useful clinical benchmarks to aid treatment decisions. Benefit and risk may also be examined using the Likelihood to be Helped or Harmed (LHH). In this post-hoc analysis, we examined the benefit-risk ratio of the four treatments using LHH. Ind
Like
Comment
Share
